ABSTRACT

Conclusion:

Young age, IVTA dose and baseline IOP higher than 15 mmHg before the IVTA injection were found as a risk factors for IOP elevation after the IVTA injection. IOP elevation after the IVTA injection within six months should be kept in mind.

Results:

Mean follow-up was 8.85 ± 7.125 months (1-41 months). Mean age of the patients was 62,7 ± 12,7 years (21-88 years). 173 (80 %) eyes received 4 mg /0.1 ml of TA, 44 (20 %) eyes received 2 mg /0.1 ml of TA. The mean baseline of IOP was 14.54 ± 1.86 mmHg (10-21 mmHg). Fifty -three eyes (%24.4) showed IOP elevation of five mmHg or higher after the IVTA injection. Fourty-eight out of 53 eyes (%90.5) received 4 mg /0.1 ml of single dose of TA. IOP was higher than 15 mmHg before the IVTA injection in 36 (68 %) out of 53 eyes. Twenty-seven (51 %) of these eyes received topical medication. Viscocanolostomy was performed in two patients. The mean age of the patients with high IOP after the injection was significantly lower than the mean age of the study group (p

Methods:

Charts of 179 patients of 217 eyes who underwent IVTA injection between January 2005- May 2007 were retrospectively reviewed. All cases underwent full ophthalmological examination before IVTA injection. Indications of IVTA injection, IVTA doses, injection times, systemic disease, history of glaucoma were noted.

Purpose:

To analyze the incidence of intraocular pressure (IOP) elevation following intravitreal triamcinolone acetonide (IVTA) injection and predictive factors for IOP elevation.